Nevro (NVRO) Scheduled to Post Quarterly Earnings on Tuesday

Nevro (NYSE:NVRO) will post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect Nevro to post earnings of ($1.02) per share for the quarter. Nevro has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

Nevro (NYSE:NVRO) last issued its quarterly earnings data on Wednesday, February 21st. The medical equipment provider reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.35. The firm had revenue of $116.18 million during the quarter, compared to analyst estimates of $115.93 million. Nevro had a negative return on equity of 30.22% and a negative net margin of 21.69%. On average, analysts expect Nevro to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nevro Stock Performance

Shares of NVRO stock opened at $11.29 on Friday. The firm has a market capitalization of $414.13 million, a price-to-earnings ratio of -4.39 and a beta of 0.96. The company has a debt-to-equity ratio of 0.72, a current ratio of 6.37 and a quick ratio of 4.94. The business has a fifty day moving average of $13.37 and a 200 day moving average of $16.34. Nevro has a 1 year low of $10.27 and a 1 year high of $28.89.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NVRO. Citigroup reduced their target price on Nevro from $18.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, April 3rd. Robert W. Baird cut their price target on Nevro from $23.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, February 22nd. Oppenheimer downgraded Nevro from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 22nd. StockNews.com upgraded Nevro from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. Finally, Mizuho dropped their target price on Nevro from $20.00 to $16.00 and set a “neutral” rating on the stock in a research report on Thursday, April 11th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Nevro presently has a consensus rating of “Hold” and an average price target of $21.23.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.